Global Blood Therapeutics Inc to Post FY2022 Earnings of $4.30 Per Share, Oppenheimer Forecasts (GBT)

Global Blood Therapeutics Inc (NASDAQ:GBT) – Research analysts at Oppenheimer issued their FY2022 earnings per share estimates for Global Blood Therapeutics in a report issued on Thursday. Oppenheimer analyst M. Breidenbach anticipates that the company will post earnings per share of $4.30 for the year. Oppenheimer has a “Buy” rating and a $79.00 price target on the stock.

Global Blood Therapeutics (NASDAQ:GBT) last posted its quarterly earnings data on Thursday, November 2nd. The company reported ($0.66) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.62) by ($0.04). During the same quarter last year, the business posted ($0.58) earnings per share.

Other analysts also recently issued reports about the company. HC Wainwright set a $73.00 price objective on Global Blood Therapeutics and gave the company a “buy” rating in a report on Thursday. Wedbush restated an “ourperform” rating and issued a $73.00 price objective on shares of Global Blood Therapeutics in a report on Monday, September 18th. BidaskClub upgraded Global Blood Therapeutics from a “hold” rating to a “buy” rating in a report on Wednesday, November 1st. ValuEngine downgraded Global Blood Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, December 1st. Finally, Needham & Company LLC assumed coverage on Global Blood Therapeutics in a report on Wednesday, September 20th. They issued a “buy” rating and a $51.00 price objective for the company. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and fourteen have issued a buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $62.07.

Shares of Global Blood Therapeutics (GBT) opened at $56.60 on Friday. Global Blood Therapeutics has a 1-year low of $14.70 and a 1-year high of $57.75.

Several hedge funds have recently added to or reduced their stakes in the company. Daiwa SB Investments Ltd. boosted its position in shares of Global Blood Therapeutics by 158.4% during the 4th quarter. Daiwa SB Investments Ltd. now owns 8,676 shares of the company’s stock worth $341,000 after purchasing an additional 5,318 shares in the last quarter. Point72 Asset Management L.P. boosted its position in shares of Global Blood Therapeutics by 189.5% during the 3rd quarter. Point72 Asset Management L.P. now owns 2,022,700 shares of the company’s stock worth $62,805,000 after purchasing an additional 1,323,934 shares in the last quarter. Perceptive Advisors LLC boosted its position in shares of Global Blood Therapeutics by 8.4% during the 3rd quarter. Perceptive Advisors LLC now owns 4,264,066 shares of the company’s stock worth $132,399,000 after purchasing an additional 330,139 shares in the last quarter. Orbimed Advisors LLC boosted its position in shares of Global Blood Therapeutics by 10.2% during the 3rd quarter. Orbimed Advisors LLC now owns 2,393,635 shares of the company’s stock worth $74,322,000 after purchasing an additional 221,700 shares in the last quarter. Finally, Janus Henderson Group PLC boosted its position in shares of Global Blood Therapeutics by 43.8% during the 3rd quarter. Janus Henderson Group PLC now owns 1,415,558 shares of the company’s stock worth $43,953,000 after purchasing an additional 431,325 shares in the last quarter. 85.72% of the stock is currently owned by institutional investors.

In other news, Director Charles J. Homcy sold 70,000 shares of the stock in a transaction dated Friday, October 27th. The shares were sold at an average price of $33.97, for a total transaction of $2,377,900.00. Following the transaction, the director now owns 83,328 shares of the company’s stock, valued at approximately $2,830,652.16. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Peter Radovich sold 15,000 shares of the stock in a transaction dated Wednesday, January 10th. The stock was sold at an average price of $50.00, for a total transaction of $750,000.00. Following the transaction, the insider now directly owns 17,684 shares in the company, valued at approximately $884,200. The disclosure for this sale can be found here. Insiders have sold 103,500 shares of company stock worth $3,773,000 in the last ninety days. Insiders own 5.30% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Global Blood Therapeutics Inc to Post FY2022 Earnings of $4.30 Per Share, Oppenheimer Forecasts (GBT)” was originally published by Stock Observer and is the sole property of of Stock Observer. If you are reading this news story on another publication, it was copied illegally and republished in violation of international trademark & copyright legislation. The legal version of this news story can be viewed at https://www.thestockobserver.com/2018/01/14/global-blood-therapeutics-inc-to-post-fy2022-earnings-of-4-30-per-share-oppenheimer-forecasts-gbt.html.

About Global Blood Therapeutics

Global Blood Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders. The Company is developing its initial product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD).

Earnings History and Estimates for Global Blood Therapeutics (NASDAQ:GBT)

Receive News & Ratings for Global Blood Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply